Allison Bratzel
Stock Analyst at Piper Sandler
(2.21)
# 1218
Out of 5,218 analysts
33
Total ratings
69.57%
Success rate
26.29%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Travere Therapeutics | Maintains: Neutral | 12 22 | 17.3 | 27.17% | 2 | Nov 14, 2024 | |
Rigel Pharmaceutical... | Maintains: Neutral | 15 23 | 18.85 | 22.02% | 2 | Nov 14, 2024 | |
Ionis Pharmaceutical... | Maintains: Overweight | 65 62 | 36.62 | 69.31% | 1 | Nov 14, 2024 | |
argenx | Maintains: Overweight | 553 620 | 606.64 | 2.2% | 12 | Nov 1, 2024 | |
Scholar Rock Holding | Maintains: Overweight | 28 42 | 42.06 | -0.14% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 22 | 11.83 | 85.97% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 4 | 4.08 | -1.96% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 8 20 | 4.93 | 305.68% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 20 | 2.81 | 611.74% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 23 25 | n/a | n/a | 1 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 44 | 12.53 | 251.16% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 | 68.61 | 45.75% | 2 | Feb 8, 2023 |